Please ensure Javascript is enabled for purposes of website accessibility

Pfizer Inc. Set Up for Big Growth in 2016

By Motley Fool Staff - Jan 4, 2016 at 9:01AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A corner turning back to growth and a cheap forward P/E ratio make this a stock investors might want to own in 2016.

Pfizer (PFE -1.18%) has not been performing well since 2012 when its patents for blockbuster drugs began to run out. The market reaction to that happening, and the company's ongoing prospects, led to its undervaluation, despite solid plans for future growth.

In this video segment, healthcare analyst Kristine Harjes and Motley Fool contributor Todd Campbell explain just what Pfizer is looking to do that's setting it up ahead of the curve for 2016, and why at the current price this stock is a bargain.

A full transcript follows the video.

 

This podcast was recorded on Dec. 21, 2015.

Kristine Harjes: Moving on to another stock that we thought sounded pretty promising and kind of cheap, is Pfizer.

Campbell: Pfizer is a favorite company for investors to have disliked since 2012, because they had lost patent protection on their $13 billion megablockbuster Lipitor, a cholesterol-busting drug. And obviously, if you lose patent protection on a drug that's generating that much of your revenue, that's going to be pretty hard to replace. You fast forward, though, a few years, and it could be that the quarter is going to turn for this company. And if it does, then paying less than 14x forward earnings to buy this stock may make a lot of sense.

Harjes: Yeah, this to me remains a long-term investing story. Everything we recommend on the show is a long-term situation. You should buy and hold for at least 5+ years. But for me, especially Pfizer -- this is not a company that is going to see a ton of growth in the next year, I would say. But it pays a really solid dividend, 3.75%, and because of that, it attracts a lot of long-term investors, which will reduce your volatility a little bit, and meanwhile, they've got a lot of irons in the fire.

They've got IBRANCE, which is their breast cancer drug, that should hit blockbuster status sometime in 2016. The recent Hospira acquisition to get into biosimilars, that should be an enormous market, and combat the threat that the company is experiencing from other competing biosimilar companies, Eliquis, the next-generation blood thinner -- there's just really a lot of things that could go well for this company, but it's going to take some time to really start to see more growth.

Campbell: This is one that maybe you sock away this Christmas and next. I think a lot of people are extrapolating the weakness they've suffered the last few years continuously out into the future. And if this company can return to mid-single-digit growth in 2016 and then build upon that as we move further into the year, and expectations for 2017 start getting priced in, I don't see a reason why you can't have the stock trade nicely higher for investors.

Kristine Harjes has no position in any stocks mentioned. Todd Campbell has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Pfizer Inc. Stock Quote
Pfizer Inc.
PFE
$49.27 (-1.18%) $0.59

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
402%
 
S&P 500 Returns
129%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/17/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.